Fitxers

695776.pdf (540.18 KB)

Tipus de document

Article

Versió

Versió acceptada

Data de publicació

2019-12-20

Llicència de publicació

cc-by-nc-nd (c) Cortex - Publicacoes Tecnicas e Cientificas, 2019
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/164999

Cost-effectiveness of insulin degludec versus insulin glargine U100 in patients with type 1 and type 2 diabetes in Portugal: evidence from SWITCH 1&2 trials

Títol de la revista

Autors

Director/Tutor

ISSN de la revista

Títol del volum

Recurs relacionat

Resum

Objectives: To assess the cost-effectiveness of insulin degludec (degludec) versus insulin glargine (glargine) U100 from a Portuguese healthcare perspective using data from SWITCH 1 & 2 trials. - - - Methods: A short-term model estimated cost-effectiveness of degludec versus glargine U100 in type 1 diabetes (T1DM) basal bolus (B/B) and type 2 diabetes (T2DM) basal oral therapy (BOT) patients. The model captured hypoglycaemia rates and insulin dosing. Clinical outcomes were obtained from SWITCH 1 & 2. Disutilities related to hypoglycaemic events and insulin, needles and blood glucose tests costs were also included. Benefits were measured in QALYs. One-way and probabilistic sensitivity analyses were conducted (...)

Matèries

Anàlisi cost-benefici, Salut pública, Diabetis, Insulina, Portugal

Matèries (anglès)

Cost effectiveness, Public health, Diabetes, Insulin, Portugal

Citació

Col·leccions

Articles publicats en revistes (Economia)

Citació

DARBÀ, Josep, et al. Cost-effectiveness of insulin degludec versus insulin glargine U100 in patients with type 1 and type 2 diabetes in Portugal: evidence from SWITCH 1&2 trials. Revista Portuguesa de Diabetes. 2019. Vol. 14, num. 4, pags. 141-150. ISSN 1646-3439. [consulted: 28 of June of 2026]. Available at: https://hdl.handle.net/2445/164999

Exportar metadades

JSON - METS

Compartir registre